Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibuprofen 600 mg IR/ER Self-selection and Compliance Study
NCT01789606Phase 3Completed
- Sponsor
- Pfizer
- Start
- Sep 2012
- Primary completion
- Jun 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ibuprofen in pain, sponsored by Pfizer. Primary endpoints: Percentage of Participants Who Correctly Select to Use or Correctly De-select Not to Use Ibuprofen 600 mg IR/ER Study Medication at Day 1, Percentage of Participants Who Correctly Select to Use or Correctly De-select Not to Use Ibuprofen 600 mg IR/ER Study Medication Excluding Those Classified as Missed Opportunity at Day 1 and 4 more. Started Sep 2012; status: completed.
02
Drugs
ibuprofen
03
Conditions
pain
Beyond the preview
Go deeper on NCT01789606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01789606.